Neuropeptide Y Plays an Important Role in the Relationship Between Brain Glucose Metabolism and Brown Adipose Tissue Activity in Healthy Adults: A PET/CT Study

What Was Tested

Researchers studied Neuropeptide Y in this controlled clinical trial publication.

The brain, especially the hypothalamus, which secretes Neuropeptide Y (NPY), is speculated to regulate BAT activity.

However, whether NPY is involved in BAT activity's central regulation in humans remains unclear.

Who Took Part

The abstract describes 80 adults taking part.

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

A controlled study with a large sample of healthy adults used Positron emission tomography/computed tomography (PET/CT) to noninvasively investigate BAT's activity and brain glucose metabolism in vivo.

Eighty healthy adults with activated BAT according to the PET/CT scan volunteered to be the BAT positive group, while 80 healthy adults without activated BAT but with the same gender, similar age, and BMI, scanning on the same day, were recruited as the control (BAT negative).

How the Study Was Run

The researchers use Statistical parametric mapping (SPM) to analyze the brain image data, Picture Archiving & Communication System (PACS), and PET/CT Viewer software to calculate the semi-quantitative values of brain glucose metabolism and BAT activity.

ELISA tested the levels of fasting plasma NPY.

The multiple linear regression models were used to analyze the correlation between brain glucose metabolism, the level of NPY, and the BAT activity in the BAT positive group.

What Was Measured

Topics PubMed links to this paper include Adipose Tissue, Brown, Brain, Carbohydrate Metabolism, China, Fluorodeoxyglucose F18, Glucose and Healthy Volunteers.

The authors tagged it with the keywords brain glucose metabolism, brown adipose tissue, neuropeptide Y, positron-emission tomography and computed tomography and statistical parametric mapping.

What This Means in Plain Language

This is a controlled clinical trial of Neuropeptide Y in 80 adults.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the Neuropeptide Y compound page, all human trials.